TLR9 and neoplasm: By administering an in situ injection of three drugs in combination, namely the TLR9 agonist CpG, agonistic anti-OX40 antibody and STING agonist cGAMP, we not only significantly slowed the growth of tumours at the injection site but also altered the growth of distant tumours.